

31 May 2022

**Response to a request for official information**

Thank you for your request for official information received 29 April 2022 by Nelson Marlborough Health (NMH)<sup>1</sup>, where you seek the following information.

1. *“How many courses of the following Covid-19 treatments have been dispensed to both inpatients and outpatients between January 1 and April 28:  
Baricitinib (Olumiant), Casirivimab with imdevimab (Ronapreve), Nirmatrelvir and Ritonavir (Paxlovid), Remdesivir (Veklury), Tocilizumab (Actemra)”*

NMH response:

Please see Table One for NMH Hospital administered therapeutics for the treatment of COVID-19 between 1 January 2022 and 28 April 2022:

**TABLE ONE**

Therapeutic for treatment of COVID-19	Number of courses
Baricitinib (Olumiant)	1
Casirivimab with imdevimab (Ronapreve)	0
Nirmatrelvir and Ritonavir (Paxlovid)	0
Remdesivir (Veklury)	13
Tocilizumab (Actemra)	11

This response has been provided under the Official Information Act 1982. You have the right to seek an investigation by the Ombudsman of this decision. Information about how to make a complaint is available at [www.ombudsman.parliament.nz](http://www.ombudsman.parliament.nz) or free phone 0800 802 602. If you have any questions about this decision please feel free to email our OIA Coordinator [OIArequest@nmdhb.govt.nz](mailto:OIArequest@nmdhb.govt.nz) I trust this information meets your requirements. NMH, like other agencies across the state sector, supports the open disclosure of information to assist the public's understanding of how we are delivering publicly-funded healthcare. This includes the proactive publication of anonymised Official Information Act responses on our website from 10 working days after they have been released. If you feel that there are good reasons why your response should not be made publicly available, we will be happy to consider.

Yours sincerely



Lexie O'Shea  
Chief Executive

<sup>1</sup> Nelson Marlborough District Health Board